NYSE - Delayed Quote USD

Elevance Health, Inc. (ELV)

439.95 -5.33 (-1.20%)
At close: October 23 at 4:00:02 PM EDT
439.95 0.00 (0.00%)
After hours: October 23 at 5:11:38 PM EDT
Trade ELV on Coinbase
Chart Range Bar
Loading chart for ELV
Chart does not reflect overnight price.

What's happening with ELV?

27m ago
Powered by Yahoo Scout

Elevance Health reported a stronger-than-expected third quarter, led by Carelon and improved Medicaid, Medicare Advantage, and Affordable Care Act performance. Management raised 2026 adjusted earnings guidance to at least $29 per share and expects at least 12% adjusted EPS growth in 2027, while membership declines and thin margins remain key risks.

Powered by Yahoo Scout
  • Previous Close 445.28
  • Open 442.27
  • Bid 431.79 x 8000
  • Ask 450.00 x 12000
  • Day's Range 439.00 - 445.40
  • 52 Week Range 274.84 - 450.69
  • Volume 1,144,955
  • Avg. Volume 1,152,332
  • Market Cap (intraday) 95.412B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) 18.68
  • EPS (TTM) 23.55
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield 6.88 (1.56%)
  • 1y Target Est 481.48
  • Morningstar Rating
    Rating available with Stock Picks access

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

www.elevancehealth.com

96,129

Full Time Employees

December 31

Fiscal Year Ends

Recent News

View More

Performance Overview

Trailing total returns as of 10/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ELV
27.34%
S&P 500 (^GSPC)
11.37%

1-Year Return

ELV
29.58%
S&P 500 (^GSPC)
13.14%

3-Year Return

ELV
2.39%
S&P 500 (^GSPC)
80.78%

5-Year Return

ELV
9.23%
S&P 500 (^GSPC)
67.74%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 50.44B
Earnings 1.36B
Profit Margin 2.71%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
10B
20B
30B
40B
50B
1.5%
2.0%
2.5%
3.0%
3.5%
 

Analyst Insights

View More

Analyst Price Targets

406.00 Low
481.48 Average
439.95 Current
523.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/23/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 465 -> 495
 

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.55%

  • Return on Assets (ttm)

    4.00%

  • Return on Equity (ttm)

    11.48%

  • Revenue (ttm)

    201.83B

  • Net Income Avi to Common (ttm)

    5.14B

  • Diluted EPS (ttm)

    23.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    37.85B

  • Total Debt/Equity (mrq)

    68.66%

  • Levered Free Cash Flow (ttm)

    7.99B

Company Insights

Research Reports

View More

People Also Watch